

## Neoadjuvant Interferons: Critical for effective PD-1–based immunotherapy in TNBC

Natasha K. Brockwell<sup>1</sup>, Katie L. Owen<sup>1</sup>, Damien Zanker<sup>1</sup>, Alex Spurling<sup>1</sup>, Jay Rautela<sup>1,#</sup>,  
Hendrika M. Duivenvoorden<sup>1</sup>, Nikola Baschuk<sup>1</sup>, Franco Caramia<sup>2</sup>, Sherene Loi<sup>2,3</sup>, Phillip K.  
Darcy<sup>2,3,4,5</sup>, Elgene Lim<sup>6,7</sup>, Belinda S. Parker<sup>1\*</sup>

<sup>1</sup> Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia

<sup>2</sup> Cancer Immunology Program, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia

<sup>3</sup> Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia

<sup>4</sup> Department of Pathology, University of Melbourne, Parkville, Victoria, Australia

<sup>5</sup> Department of Immunology, Monash University, Clayton, Victoria, Australia

<sup>6</sup> Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia

<sup>7</sup> St Vincent's Hospital, University of New South Wales, Darlinghurst, Sydney, Australia

# Current address: The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia; Department of Medical Biology, The University of Melbourne, VIC 3010, Australia

\***Corresponding author:** Belinda S. Parker, LIMS1, La Trobe University, Melbourne, VIC, Australia 3086. Email: [Belinda.Parker@latrobe.edu.au](mailto:Belinda.Parker@latrobe.edu.au). Phone: 61-3-9479-3020

**Running title:** Combination immunotherapy for triple-negative breast cancer

**Key words:** Breast cancer, metastasis, host-tumor interactions, interferon, PD1/PD-L1, immunomodulation, triple negative breast cancer, immunotherapy

**Financial support:** This work was supported by grant funding from the National Health and Medical Research Council (NHMRC, APP1047747) and Cancer Council Victoria (CCV, APP1127757) (BSP). Fellowship support from NHMRC and ARC (PKD and BSP) and the National Breast Cancer Foundation (NBCF) (fellowship to EL).

## Abstract

The lack of targeted therapies available for triple-negative breast cancer (TNBC) patients who fail to respond to first-line chemotherapy has sparked interest in immunotherapeutic approaches. However, trials utilizing checkpoint inhibitors targeting the PD-1/PD-L1 axis in TNBC have had underwhelming responses. Here we investigated the interplay between type I IFN signaling and the PD-1/PD-L1 axis and tested the impact of combining IFN inducers, as immune activators, with anti-PD-1, to induce an antimetastatic immune response. Using models of TNBC, we demonstrated an interplay between type I IFN signaling and tumor cell PD-L1 expression that impacted therapeutic response. The data revealed that the type I IFN-inducer poly(I:C) was an effective immune activator and antimetastatic agent, functioning better than anti-PD-1, which was ineffective as a single agent. Poly(I:C) treatment induced PD-L1 expression on TNBC cells, and combined poly(I:C) and anti-PD-1 treatment prolonged metastasis-free survival in a neoadjuvant setting via the induction of a tumor-specific T-cell response. Use of this combination in a late treatment setting did not impact metastasis-free survival, indicating that timing was critical for immunotherapeutic benefit. Together, these data demonstrated anti-PD-1 as an ineffective single agent in preclinical models of TNBC. However, type I IFN inducers were effective immune activators and neoadjuvant trials combining them with anti-PD-1 to induce a sustained antitumor immune response are warranted.

## Introduction

Immunotherapy has gained momentum as a viable option to treat a subset of cancers. Therapies targeting immune checkpoint proteins such as cytotoxic T-Lymphocyte antigen 4 (CTLA4) and the programmed death-1 (PD-1) receptor have revolutionized the treatment of metastatic melanoma [1], [2]. The inhibitory action of PD-1 bound to its ligand (PD-L1) dampens immune activation – a mechanism exploited by tumor cells via upregulation of cell surface PD-L1 expression to evade immune detection and subsequent tumor-cell elimination [3], [4]. Studies exploring the efficacy of treatments such as nivolumab and pembrolizumab, PD-1-specific antibodies, have demonstrated 1-year survival rates of over 73% in patients with metastatic melanoma, a vast improvement over post-chemotherapy survival [5], [6]. Extended follow up into the durable response of nivolumab reports a five-year overall survival rate of 34%; this is more than double the previous survival rate for patients with metastatic melanoma receiving chemotherapy [7]. Therefore, such agents are now being trialed in other cancer types, including breast cancer.

In breast cancer, use of anti-PD-1/PD-L1 has received most attention in the triple-negative breast cancer (TNBC) subtype. TNBC tumors have high PD-L1 expression compared to other subtypes [8], [9] and a high degree of tumor-infiltrating lymphocytes (TILs) [10], suggesting that they may be more immunogenic [11]. Additionally, due to the lack of targeted therapies available for this subtype, new approaches are urgently needed for patients who do not respond to first-line chemotherapy. Trials utilizing checkpoint inhibitors

in metastatic TNBC patients are ongoing. Reported response rates are encouraging, albeit lower than those reported in melanoma. A phase 1b trial (NCT01848834) assessing the safety and efficacy of pembrolizumab in pre-treated metastatic TNBC expressing PD-L1 reported a response rate of 18.5% in 27 patients, and limited associated toxicities [12]. In this pilot study, there was little correlation between the degree of PD-L1 positivity and clinical response. In fact, interrogation of PD-L1 expression in TNBC has revealed that high primary tumor PD-L1 expression predicts a favorable outcome [8], [9]. Furthermore, PD-L1 expression directly correlates with the degree of TILs, which is another favorable prognostic factor [10], [13], suggesting that PD-L1 expression reflects an active antitumor immune microenvironment. These studies indicate that interactions between the immune system and breast cancer cells determine cell fate and risk of metastatic relapse in TNBC.

One family of cytokines implicated in an antitumor immune response are the type I interferons (IFNs) [14], [15]. We have shown the importance of tumor-intrinsic type I IFN signals in antitumor immunity and control of metastatic progression in breast cancer, whereby loss of tumor cell IFN regulatory factor (IRF) 7, a key transcription factor in the IFN signaling pathway, occurs in bone metastases in a syngeneic TNBC mouse model [16]. Restoring tumor-cell IRF7 expression or systemic IFN $\alpha$  treatment could decrease bone metastasis and prolong survival, outcomes dependent on both innate and adaptive immune responses [16]. In support of a metastasis-suppressive role of this pathway, loss of the IFN signature in primary breast tumors is associated with an increased risk of bone metastasis in patients [16]. In multiple syngeneic TNBC mouse models, mice lacking the ability to respond to type I IFN signals [type I IFN receptor (IFNAR) deficient] are more susceptible to metastasis compared to wild-type mice [17]. Furthermore, work in melanoma shows that IFN signaling is a tumor suppressive pathway; in particular the downregulation of IFNAR1 contributes to aggressive metastatic melanoma [18]. Together, this work implicates IFN-driven crosstalk between tumor cells and immune cells in the antitumor immune response during metastatic progression.

Type I IFNs have been used to treat melanoma [19], particularly in the adjuvant setting where such treatment prolongs disease-free survival in high-risk patients [20]. However, type I IFN treatment has shown limited efficacy when tested in the context of advanced breast cancer (reviewed in [14]), possibly resulting from the lack of randomization within trials, coupled with treatment in late-stage treatment-refractory patients. Although few trials have explored the early treatment setting, several Toll-like receptor (TLR) agonists known to induce type I IFNs have demonstrated activity in early-stage breast cancer [14], [21]. The combination of the TLR3 agonist poly(A:U) and chemotherapy (cyclophosphamide, methotrexate and 5-fluoro-uracil) or radiotherapy improved overall survival and 5-year relapse-free survival [14], [22]. Despite this, the benefit of poly(A:U) or other IFN-based treatments as single agents or adjuvants to chemotherapy and radiotherapy has yet to be explored in early-stage TNBC trials.

Type I IFN-based treatments lead to upregulation of a multitude of IFN-stimulated genes (ISGs) implicated in anticancer immune responses [14], [23], [24]. This includes tumor-intrinsic changes (antigen presentation and stress ligand expression) and the activation of adaptive and innate immune components, such as CD8<sup>+</sup>, CD4<sup>+</sup> T lymphocytes and natural killer (NK) cells [14], [15], [24], as well as promoting the secretion of IFN $\gamma$  – a type II IFN that is cytotoxic [25], [26]. However, an intrinsic brake on the IFN-based stimulation of immunity is the upregulation of immune checkpoints including PD-L1 and PD-1 [27], which deactivate immune cells, largely to prevent autoimmunity [28]. Such homeostatic strategies however, could reduce the sustained impact of IFN-based therapeutic strategies. In line with this, therapeutic approaches combining immune activating agents with checkpoint blockade may be a viable immunotherapeutic strategy in patients.

This study investigates the utility of targeting type I IFN activation against, and in combination with anti-PD-1, in both early and late treatment settings. As IFN-based immune activation can cause secondary dampening of immunity via PD-L1 induction [28], we hypothesized that PD-1 blockade would result in durable responses from immune activating therapies. We show that PD-1 blockade alone was ineffective as a single agent in several TNBC models regardless of treatment timing. We highlighted the anti-metastatic effect of targeting type I IFN activation via poly(I:C) administration and that its therapeutic benefit could be sustained via co-administration of anti-PD-1, particularly in the neoadjuvant treatment setting, and that this was associated with a sustained antitumor CD8<sup>+</sup> T-cell response.

## Materials and Methods

### Cell lines and mice

Human breast cancer cell lines were obtained from ATCC and DMSZ. TNBC cell lines were grown in DMEM supplemented with 10% FBS (Gibco) (CAL-120, MDA-MB-231, SUM159, HCC70, BT20, HCC1806) or RPMI supplemented with 10% FCS + 5 $\mu$ g/ml insulin (Sigma) (BT549, SUM149, MDA-MB-456), HER2<sup>+</sup> (HCC1954, SKBR3, MDA-MB-453) and ER<sup>+</sup> (BT483, T47D, MCF7) cell lines were also grown in 10% RPMI. Murine cell lines (67NR, 66cl4, 4T07 and 4T1) were sourced from Dr Fred Miller who derived the cell lines from a spontaneous mammary tumor that arose in a BALB/c mouse [29]. The highly-metastatic 4T1.2 sub clone of the 4T1 line was derived in and sourced from Prof Robin Anderson's laboratory [30], [31]. The EO771 cell line was derived from a spontaneous primary tumor in a C57BL/6 mouse and was kindly provided by Prof Robin Anderson [32]. All cells were engineered to express the mCherry and/or luciferase (Luc2) reporter genes through retroviral transduction (MSCV). BALB/c cell lines were cultured in  $\alpha$ -MEM (5% FBS) and C57BL/6 cell lines were cultured in DMEM (10% FBS). All cell lines (human/murine) were passaged using EDTA (0.01% w/v in PBS) and cultured for no longer than 4 weeks. Tumor

lines were verified to be *mycoplasma* negative by the Victorian Infectious Diseases References Lab at regular intervals and before *in vivo* injection of cell lines (Melbourne, Vic, Australia).

C57BL/6 and BALB/c mice were obtained from the Walter and Eliza Hall Institute of Medical Research (Melbourne, Vic, Australia) and the Animal Resources Centre (Perth, WA, Australia). Mice were used between the ages of 8-12 weeks. All experiments were approved by the La Trobe Animal Experimentation ethics committee.

### Flow cytometry analysis

Analysis of cell surface PD-L1 expression *in vitro* and *in vivo* (circulating and infiltrating lymphocytes) was completed by flow cytometry using the FACS Canto II (BD Biosciences) and data analyzed using Flowjo software (Tree Star). To assess PD-L1 induction by IFN $\alpha$  (250 IU/ml, 500 IU/ml or 1000 IU/ml) and IFN $\gamma$  (5ng/ml, 10ng/ml & 20ng/ml; Shendoah) cell lines were treated 48 hours prior to flow cytometry. Poly(I:C) (10 $\mu$ g/ml) in the presence or absence of MAR1 (10 $\mu$ g/ml; LifeTechnologies) was transfected into cells using lipofectamine 2000 (10 $\mu$ g/ml, LifeTechnologies) 24 hours prior to flow cytometry. Cells were stained with CD274-PE (Human; 1:50, M1H5; Cell Signalling Technologies, Mouse; 1:300, M1H5; BD biosciences), IFNAR1-APC (1:300, MAR1-5A3; Biolegend) or relevant isotype controls (Human; mouse IgG1  $\kappa$ ; Cell Signalling Technologies, Mouse; rat IgG2a  $\kappa$ ; Mouse IgG1  $\kappa$  eBiosciences; Biolegend). Data is represented as normalized mean fluorescence intensity (MFI) where the median fluorescent intensity and standard deviation of the sample is normalized to the isotype control.

$$(\text{sampleMFI} - \text{isotypeMFI}) \div (\text{sampleRobustSD} + \text{isotypeRobustSD})$$

### Immune cell analysis

Blood obtained from the submandibular vein was used to profile circulating immune cells after red blood cell (RBC) lysis (155mM NH $_4$ Cl, 10mM KHCO $_3$ , 0.1mM EDTA, pH 7.3). Cells were stained with the following antibodies : CD8a-PE-Cy7 (53-6.7), CD4-APC-Cy7 (GK1.5), CD69-APC (H1.2F3), CD44-FITC (1M7), CD62L-BV421 (MEL-14), CD279-PE (J43), NK1.1-APC-Cy7 (PK136), NKP46-A700 (29A1.4), TCR $\beta$ -FITC (H57-597), CD11b-BV421 (M1/70), CD27-PerCP (LG-7F9) (all from BD Biosciences) and NKG2D-PE-Cy7 (CX5) (eBioscience) before being subject to flow cytometry analysis.

Analysis of tumor-infiltrating lymphocytes was as above with the addition of mechanical and enzymatic (1mg/ml collagenase I (Sigma) and 30 $\mu$ g/ml DNase I (Sigma) at 37°C) digestion to obtain a single cell suspension before RBC lysis.

### Intracellular cytokine staining (ICS) for IFN $\gamma$

To assess the number of antigen (Ag) specific CD8 $^+$  T cells present in the lungs of mice a single cell suspension was obtained using mechanical and enzymatic (1mg/ml collagenase I (Sigma) and 30 $\mu$ g/ml DNase I (Sigma) at 37°C) digestion before RBC lysis

(155mM NH<sub>4</sub>Cl, 10mM KHCO<sub>3</sub>, 0.1mM EDTA, pH 7.3). Cell suspension was then re-stimulated with 4T1.2 cells for 5 hours in the presence of brefeldin A (BFA) (10µg/ml, Sigma) before staining with CD8α-APC (53-6.7; BD biosciences) followed by IFNγ-PE (XMG1.2; BD biosciences) in the presence of saponin (0.4% v/v) (as previously described by Zanker *et. al* [33]). Samples were then subject to flow cytometry using the FACSCanto II (BD Biosciences) and data analyzed using Flowjo software (Tree Star).

### **Bioinformatic interrogation of breast cancer TCGA gene expression data**

The TCGA Human Breast Invasive Carcinoma normalized RNA quantities were accessed using the Firehose platform [34]. The IFN [16], [35] and IFN core (HBEGF, STAT1, IRF7, IFI44, IL13RA1, CD86, CSF2RB, CD44, TLR3, IER3, IFITM3, RUNX3, CTSS ) signatures were compared to PDL1 (CD274) expression. Pearson correlation coefficients (r), scatter plots and significance values were computed in R (version 3.3.2).

### ***In vivo* treatment and metastasis analysis**

For *in vivo* experiments, 1x10<sup>5</sup> cells (EO771 or 4T1.2) were re-suspended in PBS and injected into the 4<sup>th</sup> mammary fat pad (IMFP) in a 20µl volume on day 0. Poly(I:C) (25µg/mouse; Sigma) or saline was administered intravenously (IV), whereas anti-PD-1 (RPM1-14, Bioxcell) IgG (2A3, Bioxcell) was administered intraperitoneal (IP) at 250µg/mouse. To evaluate the effect of poly(I:C) on immune cell activation in 4T1.2 tumor-bearing mice poly(I:C) was administered thrice weekly from days 2-11 post tumor cell inoculation.

Mice receiving the combined treatment strategy (treatment before and after primary tumor resection) were randomized into groups and administered poly(I:C) on days 6, 8, 11, 13, 15 and 18 and anti-PD-1 on days 8, 11, 15 and 18.

For the late treatment setting, after primary tumor removal, mice received poly(I:C) on days 13, 15, 18, 20, 22 and 25, and anti-PD-1 on days 15, 18, 22 and 25.

For the neoadjuvant treatment setting mice received poly(I:C) on days 2, 4, 6, 9 and 11, and anti-PD-1 on days 4, 6, 9 and 11.

Mammary tumors were resected on day 12 (BALB/C) or day 15 (C57BL/6) post-tumor cell inoculation and weighed. Mice were sacrificed upon signs of metastatic distress with all mice being taken at the same time point for metastasis assays. At end point, mice were imaged using an IVIS Lumina XR-III (Caliper Life Sciences, Australia) under inhaled isoflurane anesthesia before lungs were rapidly excised and subjected to *ex vivo* imaging. mCherry fluorescence or bioluminescent intensity (12 minutes post-IP injection of 1.5mg D-Luciferin; Gold technology) was measured and normalized between all images in a group using Living Image 4.4 software (Caliper Life Sciences). Metastatic burden was assessed using quantitative real-time PCR as described below. Survival curves were generated using Prism (GraphPad).

### **Quantification of metastatic burden**

Real-time (RT) qPCR was used to quantify metastatic burden (as previously described by Eckhardt *et al.* [36]) by comparing the ratio of mCherry (present in tumor cells) to vimentin (NC\_000068, present in all cells) sequences in genomic DNA preparations from homogenized and proteinase K (100µg/ml, Merck) digested lungs and spines. PCR reactions were performed using SsoAdvanced universal probes supermix reagents (BioRad) and C100 Thermal Cycler with CFX96/CFX384 RealTime System module (BioRad) and primers were as follows: mCherry FWD: 5'-GACCACCTACAAGGCCAAGAAG-3'; REV: 5'-AGGTGATGTCCAACCTTGATGTTGA-3'; hydrolysis probe: 5'/56-FAM/CAGCTGCCC/ZEN/GGCGCCTACA/3IABkFQ/3': mVimentin FWD: 5'-AGCTGCTAACTACCAGGACACTATTG-3'; REV: 5'-CGAAGGTGACGAGCCATCTC-3'; hydrolysis probe: 5'HEX/CTTTCATGTTTTGGATCTCATCTGCAGG/TAMRA/3'. Metastatic burden (arbitrary units; AU) was based on the quantification cycle ( $C_q$ ) for mCherry relative to vimentin and displayed as relative tumor burden (RTB) using the following equation:  $RTB = 10000 / (2^{\Delta C_q})$ , where,  $\Delta C_q = C_q(\text{targetgene}) - C_q(\text{control})$

### Histology and immunohistochemistry (IHC)

Prior to paraffin embedding and sectioning, all tissues were fixed in 10% neutral buffered formalin for 24 hours. For detection of PD-L1 expression tissues were subjected to heat-induced epitope pressure cooker retrieval (110°C for 5 min) in EDTA buffer (1mM EDTA, pH 8) before incubating with anti-PD-L1 (AF1019; 1µg/ml, R&D biosystems) at 4°C overnight. Tissues were then incubated with enzyme conjugated secondary antibody followed by incubation with Avidin/Biotinylated enzyme Complex (ABC) (Vectastain) and visualisation with the diaminobenzidine (DAB) (Vectastain) color development system. Tissues were counterstained using hematoxylin.

### Statistical analysis

Student's two-tailed *t*-tests were used to evaluate significant differences between groups. Mantel-Cox log-rank tests were used to evaluate differences in survival time. GraphPad Prism software (GraphPad) was used for all analyses.  $P < 0.05$  was considered statistically significant.

## Results

### IFNs induced PD-L1 expression in TNBC primary tumors

To determine the heterogeneity of PD-L1 expression we first assessed differences in cell surface PD-L1 expression using flow cytometry across a range of cell lines, representing different subtypes. Of the cell lines evaluated, the TNBC subtype expressed the highest baseline PD-L1 expression (Fig. 1A). HER2<sup>+</sup> (ER-/PR-/HER2 amplified) and ER<sup>+</sup> cell lines expressed varying levels of PD-L1, however ER<sup>+</sup> cells demonstrated the lowest expression (Fig. 1A). Although this pattern was concordant with PD-L1 expression in patient tissue

cohorts [8], [9], expression was variable within our cell lines (Fig. 1A). As PD-L1 is an ISG and is induced in tumor cells by IFN $\gamma$  [37], we assessed the impact of IFN $\alpha$  and IFN $\gamma$  on cell surface expression of PD-L1 in breast cancer cells. After a 48-hour incubation, IFN $\alpha$  and IFN $\gamma$  treatment induced PD-L1 cell surface expression in a range of human breast cancer cell lines (Fig. 1B).

The cell line work suggested a correlation between IFN signaling and PD-L1 expression. To test whether such a correlation exists in patient-derived breast tumors, we utilized the TCGA RNAseq database to compare the expression of our previously identified type I IFN gene signature ([16], [35]) and PD-L1. We identified a correlation between the IFN signature and also a core list we have developed that represents an active signaling pathway (HBEGF, STAT1, IRF7, IFI44, IL13RA1, CD86, CSF2RB, CD44, TLR3, IER3, IFITM3, RUNX3, CTSS) and PD-L1 expression (Fig. 1C, D). A link between therapeutic IFN induction and PD-L1 expression in patients is yet to be tested, although our results support a link between an active type I IFN state and PD-L1 in TNBC patients.

### **IFN and IFN-agonists increase PD-L1 expression both *in vitro* and *in vivo***

As with the human cells lines, mouse lines exhibited heterogeneous baseline PD-L1 cell surface expression. The BALB/C series of cell lines (derived from a syngeneic TNBC mouse model) are well characterized for their metastatic propensity [29], [31]. We observed that PD-L1 expression was higher in the non-metastatic 67NR and weakly metastatic 66cl4 cell lines than in the highly metastatic 4T1 and 4T1.2 cell lines (Fig. 2A). The inverse correlation between PD-L1 expression and risk of metastasis is consistent with reports in TNBC patient tissues [8], [9]. Regardless of baseline PD-L1 expression, both IFN $\alpha$  and IFN $\gamma$  induced PD-L1 expression, up to 8- and 17-fold respectively (Fig. 2A). Varying doses of IFN revealed a dose-dependent increase in PD-L1 expression (Supplementary Fig. S1A, B). As TLR agonists that stimulate IFN production are being trialed clinically, we wanted to test whether the TLR3 agonist poly(I:C) also increased PD-L1 expression. Transfection of cells with poly(I:C) for 24 hours significantly upregulated cell surface PD-L1 expression ( $P > 0.05$ ). Addition of MAR1, a type I IFN $\alpha$  receptor (IFNAR) blocking antibody, abrogated poly(I:C) induced PD-L1 upregulation (Fig. 2B), confirming that poly(I:C) is stimulating PD-L1 expression via type I IFN production/signaling. This finding was independent of intrinsic IFNAR expression, with no differences detected between all cell lines evaluated (Supplementary Fig. S1C) Next, we evaluated expression of PD-L1 in orthotopic 4T1 mammary tumors derived from mice that had either received recombinant IFN $\alpha$  or a vehicle control. Our results demonstrate an increase in intratumoural expression of PD-L1 in mice treated with IFN $\alpha$  compared to untreated (Fig. 2C, no detectable expression in control to moderate expression in 50-60% cells in treatment group). Similarly, there was an increase in the number of PD-L1 positive tumor cells and higher staining intensity in the 4T1.2 (30%, moderate intensity in control to 70% moderate-high intensity with treatment) and E0771 (5% low intensity to > 70% high intensity staining) tumors of mice treated with poly(I:C) (Fig.

2C). These results were concordant with our *in vitro* analysis. Taken together, this data demonstrates that tumor cell PD-L1 expression can be induced by IFN, and supports the hypothesis that PD-L1 is a marker of elevated immune signaling.

We also characterized the expression of activation ligands and PD-1 on the surface of circulating immune cells in tumor-bearing mice treated with poly(I:C). As expected, poly(I:C) led to enhanced CD4<sup>+</sup> and CD8<sup>+</sup> T- and NK-cell activation as indicated by the increase in activation ligands (CD69/NKG2D) (Supplementary Fig. S2A, B). Further analysis of the NK cells revealed an increase in CD27<sup>+/+</sup>CD11b<sup>+</sup> expression (Supplementary Fig. S2C). CD27<sup>+</sup>CD11b<sup>+</sup> NK cells have an enhanced ability to secrete cytokines, and CD27<sup>+</sup>CD11b<sup>+</sup> NK cells have efficient cytolytic function [38]. Our results suggest that poly(I:C) treatment may enhance NK-cell activation and effector function, consistent with the known action of IFNs on immune activation. Both T and NK cells express PD-1, with poly(I:C) further increasing this expression, an effect more pronounced on NK cells (Supplementary Fig. S2D). Together, this suggested responses to poly(I:C) treatment could be improved if treatment also included anti-PD-1 to block the tumor cell PD-L1 interaction with cytotoxic T-cell or NK-cell PD-1 to further enhance an antitumor immune response.

### **Poly(I:C) and anti-PD-1 combination treatment slowed tumor growth and metastases**

The EO771-mCherry syngeneic model was used to assess the impact of poly(I:C) and/or anti-PD-1 on primary tumor growth. Cells were injected intra mammary fat pad (IMFP) and mice received a priming dose of poly(I:C), followed by the combination of poly(I:C) and anti-PD-1 or single agent therapy (Fig. 3A). Analysis of primary tumor weight on day 15 after tumor cell inoculation revealed that combination therapy reduced tumor weight, whereas single agents alone did not impact primary tumor size compared to control (Fig. 3B). At day 15 post-primary tumor resection, mCherry tumor cells were visualized by *ex vivo* fluorescence imaging and a reduction in lung metastatic burden was evident in the combination therapy group. Quantification of mCherry fluorescence revealed that both poly(I:C) alone and in combination with anti-PD-1 decreased lung metastasis (Fig. 3C, D). Such an impact was not observed in the anti-PD-1 treatment group that received anti-PD-1 alone.

Analysis of circulating immune cells during treatment confirmed an increase in the proportion of T cells expressing CD69 in the combination treatment group (Supplementary Fig. S3A). Furthermore, analysis of the CD8<sup>+</sup> T cells revealed an increase in the percentage of CD44<sup>+</sup>CD62L<sup>+</sup> populations on day 14 in response to the combination treatment (Supplementary Fig. S3). Evidence suggests that CD44<sup>+</sup>CD62L<sup>+</sup> CD8<sup>+</sup> T cells are representative of a central memory population [39], suggesting that poly(I:C) both alone and in combination with anti-PD-1 can increase the central memory population.

### **Poly(I:C) and anti-PD-1 combination treatment increases tumor-specific T-cell response**

In order to assess the impact of combination therapy in a more aggressive model, we used the highly metastatic 4T1.2-luc2 cell line. Cells were injected IMFP into BALB/C mice

and treatment initiated when tumors were palpable (day 6) (Fig. 4A). Analysis of primary tumor weight on day 12 post-inoculation revealed that the combination therapy significantly decreased primary tumor weight compared to single agents alone ( $P > 0.05$ ) (Fig. 4B). Ten days after primary tumor resection, bioluminescence was used to detect 4T1.2 lung metastases *in vivo* and *ex vivo*. Bioluminescence was visibly decreased in the combination therapy group, indicating a reduction in overall metastatic burden (Fig. 4C), specifically in the lung (Fig. 4D). Quantitative DNA analysis of resected organs confirmed that combination treatment reduced metastatic burden in the lungs (Fig. 4E) of these mice compared to single agent and control treated mice. Analysis of the lymphocyte population in the lungs of these mice revealed that the combination therapy significantly increased the number of tumor cell-specific IFN $\gamma$ -producing CD8<sup>+</sup> T cells compared to poly(I:C) ( $P > 0.05$ ) (Fig. 4F, G). This increase in CD8<sup>+</sup> T-cell activity offers some rationale into the effectiveness of combining poly(I:C) and anti-PD-1 therapy.

### **Combination therapy was more effective in a neoadjuvant treatment setting**

Having shown that the combination therapy was successful in this model, we wanted to test its impact in treatment settings relevant to the clinical context, mimicking either an early neoadjuvant setting before the detection of overt metastases or a late treatment setting whereby treatment commenced after primary tumor resection when metastases are detectable.

For the early neoadjuvant treatment setting, treatment commenced on day 2, and was ceased prior to primary tumor resection (Fig. 5A). Analysis of primary tumor weight revealed that poly(I:C) treatment reduced primary tumor weight compared to vehicle control and anti-PD-1 therapy groups (Fig. 5B), and the effect was more pronounced with combination therapy (Fig. 5B). Anti-PD-1 treatment alone had no effect on primary tumor weight. Analysis of tumor-infiltrating lymphocytes revealed that both single agents and combination therapy increased the total number of TILs (Fig. 5C). However, when we assessed the nature of these TILs, we found that only poly(I:C) treatment increased the percentage of CD8<sup>+</sup> and CD4<sup>+</sup> T cells expressing CD69 (Fig. 5D). Both poly(I:C) and the combination therapy increased the percentage of NK cells expressing CD69/NKG2D, suggesting an increase in the activation status of immune cells infiltrating the primary tumor (Fig. 5E). During treatment, we also assessed circulating immune cells where we detected an increase in the percentage of CD69<sup>+</sup> and CD27<sup>+/−</sup>CD11b<sup>+</sup> expressing NK cells in the poly(I:C) and the combination groups on day 10 (Fig. 5F). Thus, poly(I:C) not only increased TIL activation but also circulating immune cells, the latter of which likely combats metastatic spread.

We next assessed the impact of therapy on metastatic burden. Bioluminescent imaging of the thoracic cavity 11 days post tumor-resection (experimental end point) revealed reduced lung metastasis in poly(I:C) and combination treated mice (Fig. 6A, B). RT-qPCR analysis revealed that, again, anti-PD-1 therapy alone had no impact on lung metastasis and that both poly(I:C) and the combination therapy abrogated metastatic burden in the lungs in the neoadjuvant setting (Fig. 6C). Analysis of immune populations in

the lung revealed that only combination therapy induced IFN $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells (Fig. 6D, E), suggesting that the addition of anti-PD-1 to poly(I:C) therapy was required to induce a sustained T-cell antitumor response and that this could prolong metastasis-free survival. To test, this we performed metastasis-free survival studies, mimicking the neoadjuvant setting with mice being individually monitored for evidence of metastasis (Fig. 7A). Poly(I:C) single agent therapy prolonged metastasis-free survival compared to control, yet anti-PD-1 alone had no impact on survival (median survival- 30, 25 and 24 days respectively; Fig. 7B). Combination therapy significantly extended overall survival in this aggressive model (median survival, 38 days; Fig. 7B,  $P > 0.05$ ) compared to single agents alone, supporting the combination of poly(I:C) and anti-PD-1 for prolonged antitumor immune response.

Such a survival benefit was not observed in a late treatment setting, in the absence of a primary tumor. We again used the highly metastatic 4T1.2-luc cells, which were injected IMFP and treatment was initiated after primary tumor resection (Fig. 7C). Comparison of survival between treatment groups revealed that neither single agents or combination therapies had an impact on metastasis-free survival, with a median survival of 23-24 days for all groups (Fig. 7D). This was in stark contrast to the observed impact of such therapies in the neoadjuvant setting, suggesting that immune-mediated elimination of tumor cells was not effective against overt metastases in the absence of a primary tumor.

## Discussion

This study highlights the anti-metastatic effects of targeted type I IFN activation in multiple models of TNBC. Analysis of the interplay between IFNs and PD-L1 expression revealed the secondary upregulation of PD-L1 and PD-1 in response to enhanced immune activation and IFN production. Our *in vivo* analyses into co-administration of anti-PD-1 and poly(I:C) revealed that anti-PD-1 is ineffective as a stand-alone agent but can prolong the antitumor T-cell response and therapeutic benefit of poly(I:C), specifically in the neoadjuvant setting.

Investigating the interplay between enhanced IFN signaling and PD-L1 expression, confirmed PD-L1 as an IFN-regulated gene in TNBC. PD-L1 is a known ISG that is upregulated in response to immune activating cytokines in both tumor and tumor-associated stromal cells [40]. We found that a key set of type I IFN genes, encompassing essential transcription factors, correlated with PD-L1 expression in TNBC, as described by other groups in primary and metastatic melanoma [41]. Tumoral PD-L1 expression reflects an active antitumor microenvironment [42], offering support as to why PD-L1 is a good prognostic factor in TNBC [8], [9]. PD-L1 expression correlates with the presence of TILs, and tumors that are rich in immune cells or 'hot' have been associated with a better prognosis in both TNBC and melanoma [10], [43]–[45]. We have also previously shown that retained tumor-intrinsic IFN in the primary tumor is associated with increased relapse-free survival in breast cancer [16].

By using a treatment that directly enhances IFN signaling both in tumor and immune cells, we increased the intratumoral and microenvironmental immune activation in previously 'immune cell poor' or 'cold' tumors, which resulted in improved survival outcomes. As noted previously, there is a lack of utility of IFN-based treatments in breast cancer due to the inconsistent efficacy data in late metastatic treatment settings [14]. Our data supports the ineffectiveness of IFN-based treatments in the late metastatic treatment setting where poly(I:C) offered no survival benefit at all. This is in support of the continued success of IFN treatment in adjuvant high risk melanoma, where it is used before overt metastases are present [20]. Our study demonstrated that a neoadjuvant approach with poly(I:C) treatment was better for suppressing metastatic spread than later treatment settings. A benefit of a neoadjuvant approach rather than late stage immunotherapy in TNBC has also been reported by others [46], and is consistent with previous breast cancer trials where poly(A:U) showed most promise in an early treatment setting [14]. We hypothesize that a loss of intrinsic IFN signaling in the tumor may predict benefit from IFN-based therapies.

Clinical trials designed to test the efficacy of anti-PD-1/PD-L1 agents in breast cancer include patients have been based on the presence of tumoral PD-L1 expression. Our work however, along with other work in breast and melanoma, suggests that baseline PD-L1 expression is not a sufficiently sensitive predictor of response [6], [12]. In a phase 1b clinical trial where TNBC patients were recruited based on PD-L1 positivity (> 1%), the efficacy of pembrolizumab was underwhelming with a response rate of 18.5% [12]. Another study suggested that anti-PD-1 was an effective single agent in a neoadjuvant TNBC mouse model [46]. Our data, on the other hand, shows a lack of efficacy of anti-PD-1 as a single agent in multiple models of TNBC. Others have similarly found a lack of response to anti-PD-1 in mouse models of TNBC [47]. The lack of anti-metastatic effect of anti-PD-1 reveals the inability of anti-PD-1 alone to induce an antitumor immune response. This demonstrates that a potent immune stimulator in addition to anti-PD-1 is required for an anti-metastatic response. In line with a link between anti-PD-1 response and an active tumor-infiltrate, increased CD8<sup>+</sup>, CD3<sup>+</sup> and CD45RO<sup>+</sup> T-cell densities at the invasive tumor margin correlate with response to anti-PD-1 in melanoma [48]. Although we have shown that both anti-PD-1 and poly(I:C) alone and in combination increase intratumoral lymphocytes, our data demonstrates that it is the nature of such TILs that correlate with response to therapy. Anti-PD-1 treatment alone was not sufficient for TIL activation in our study, whereas combination with poly(I:C) enhanced both T-cell and NK-cell activation, essentially heating up a previously immune-inactive tumor to promote antitumor response and benefit from anti-PD-1 therapy. Melanoma studies support this proposition, whereby stimulation of IFN signaling and immune activation in immune cell poor melanomas is necessary for anti-PD-1 treatment to be effective [41].

Although poly(I:C) was an effective agent in the neoadjuvant setting in our study, we also demonstrate a therapeutic benefit with the addition of anti-PD-1. The increase in

overall survival from the combination therapy in a neoadjuvant setting is likely due to the induction of a tumor specific T-cell response, which works to eliminate metastases. In the context of neoadjuvant therapy, the presence of the primary tumor *in situ* allows for the priming of tumor-specific cytotoxic T cells [46]. The combination therapy, which was superior to single agents in overall survival, correlated with an increase in tumor-specific cytotoxic T cells at the site of metastasis. This finding suggests that the combination therapy induced a self-renewing residential memory population within metastases, as demonstrated by elevated IFN $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells persisting in the lung up to 12 days after treatment cessation, which is after the T-cell contraction phase. Induction of a memory population is likely critical for a sustained anti-metastatic therapeutic response given that breast cancer recurrence can occur years after initial diagnosis [49]. The immune targeting of micrometastases before the formation of overt metastases would represent a major therapeutic advance in TNBC. Others have also shown that targeting multiple suppressive pathways is more effective than using single agents alone [2], [47], [50], [51]. Here we demonstrate that increasing immune activation through type I IFN stimulation can enhance the efficacy of anti-PD-1 in TNBC through induction of a tumor-specific immune response. Studies that have sought to increase tumor intrinsic interferon signaling alone or in combination with anti-PD-1 in other cancers have also had successes, particularly with treatments that can activate cytotoxic T cells and decrease immune suppressive populations [41], [52], [53].

In summary, we have demonstrated the ineffectiveness of anti-PD-1 as a single agent and the potential clinical use of combination type I IFN inducers and anti-PD-1 therapy in preclinical TNBC models. Our findings reveal that IFN signaling must be stimulated to promote immune activation in order for anti-PD-1 to be effective. These findings should be considered when designing clinical trials evaluating anti-PD-1 therapies in TNBC. Future research into tumor-intrinsic IFN markers as predictive biomarkers of response to IFN-based and anti-PD-1 therapies is needed. Our research suggests that patients with immune 'cold' tumors can be primed to respond to anti-PD-1 therapy via type I IFN-based therapy, and that elevated tumor-cell expression of PD-L1 may serve as a biomarker for this therapeutic approach.

This study highlights the anti-metastatic effects of targeted type I IFN activation in multiple models of TNBC. Analysis of the interplay between IFNs and PD-L1 expression revealed the secondary upregulation of PD-L1 and PD-1 in response to enhanced immune activation and IFN production. Our *in vivo* analyses into co-administration of anti-PD-1 and poly(I:C) revealed that anti-PD-1 is ineffective as a stand-alone treatment but can prolong the antitumor T-cell response and therapeutic benefit of poly(I:C) in the neoadjuvant setting. Given current clinical trials using TLR agonists in oncology [54], our combination therapy can be directly translated into the clinical setting.

## Acknowledgements

We acknowledge La Trobe Animal Research Training Facility (LARTF) for their support with animal work.

## References

- [1] C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, *et al.*, "Ipilimumab plus dacarbazine for previously untreated metastatic melanoma," *N Engl J Med*, vol. 364, no. 26, pp. 2517–2526, 2011.
- [2] P. A. Ott, F. S. Hodi, and C. Robert, "CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients," *Clin Cancer Res*, vol. 19, no. 19, pp. 5300–5309, 2013.
- [3] K. Kataoka and S. Ogawa, "Novel mechanism of immune evasion involving PD-L1 in various cancers," *Transl. Cancer Res.*, vol. 5, no. 4, 2016.
- [4] G. L. Beatty and W. L. Gladney, "Immune escape mechanisms as a guide for cancer immunotherapy," *Clin. Cancer Res.*, vol. 21, no. 4, pp. 687–692, Feb. 2015.
- [5] C. Robert, G. V Long, B. Brady, C. Dutriaux, M. Maio, L. Mortier, *et al.*, "Nivolumab in Previously Untreated Melanoma without BRAF Mutation," *N Engl J Med*, vol. 372, no. 4, pp. 320–330, 2015.
- [6] C. Robert, J. Schachter, G. V Long, A. Arance, J. J. Grob, L. Mortier, *et al.*, "Pembrolizumab versus Ipilimumab in Advanced Melanoma," *N Engl J Med*, vol. 372, no. 26, pp. 2521–2532, 2015.
- [7] F. S. Hodi, H. Kluger, M. Sznol, R. Carvajal, D. Lawrence, M. Atkins, *et al.*, "Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial," *Cancer Res.*, vol. 76, no. 14 Supplement, p. CT001 LP-CT001, 2016.
- [8] R. K. Beckers, C. I. Selinger, R. Vilain, J. Madore, J. S. Wilmott, K. Harvey, *et al.*, "Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome," *Histopathology*, vol. 69, no. 1, pp. 25–34, 2016.
- [9] R. Sabatier, P. Finetti, E. Mamessier, J. Adelaide, M. Chaffanet, H. R. Ali, *et al.*, "Prognostic and predictive value of PDL1 expression in breast cancer," *Oncotarget*, vol. 7, no. 7, pp. 5449–5469, 2015.
- [10] H. Wimberly, J. R. Brown, K. A. Schalper, H. Haack, M. R. Silver, C. Nixon, *et al.*, "PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer," *Cancer Immunol Res*, no. 4, pp. 326–332, 2014.
- [11] L. D. Miller, J. A. Chou, M. A. Black, C. Print, J. Chifman, A. Alistar, *et al.*, "Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.," *Cancer Immunol. Res.*, vol. 4, no. 7, pp. 600–610, 2016.
- [12] R. Nanda, L. Q. M. Chow, E. C. Dees, R. Berger, S. Gupta, R. Geva, *et al.*,

- “Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study,” *J. Clin. Oncol.*, vol. 34, no. 21, pp. 2460–2467, 2016.
- [13] H. R. Ali, E. Provenzano, S.-J. Dawson, F. M. Blows, B. Liu, M. Shah, *et al.*, “Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients,” *Ann. Oncol.*, 2014.
- [14] B. S. Parker, J. Rautela, and P. J. Hertzog, “Antitumour actions of interferons: implications for cancer therapy,” *Nat Rev Cancer*, vol. 16, no. 3, pp. 131–144, 2016.
- [15] J. B. Swann, Y. Hayakawa, N. Zerafa, K. C. Sheehan, B. Scott, R. D. Schreiber, *et al.*, “Type I IFN contributes to NK cell homeostasis, activation, and antitumor function,” *J Immunol*, vol. 178, no. 12, pp. 7540–7549, 2007.
- [16] B. N. Bidwell, C. Y. Slaney, N. P. Withana, S. Forster, Y. Cao, S. Loi, *et al.*, “Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape,” *Nat Med*, vol. 18, no. 8, pp. 1224–1231, 2012.
- [17] J. Rautela, N. Baschuk, C. Y. Slaney, K. M. Jayatilleke, K. Xiao, B. N. Bidwell, *et al.*, “Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-Cell Antitumor Function in Multiple Models of Breast Cancer,” *Cancer Immunol Res*, 2015.
- [18] Y. V Katlinskaya, K. V Katlinski, Q. Yu, A. Ortiz, D. P. Beiting, A. Brice, *et al.*, “Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.,” *Cell Rep.*, vol. 15, no. 1, pp. 171–180, Apr. 2016.
- [19] R. Di Trolio, E. Simeone, G. Di Lorenzo, C. Buonerba, and P. A. Ascierto, “The use of interferon in melanoma patients: A systematic review,” *Cytokine Growth Factor Rev.*, vol. 26, no. 2, pp. 203–212, 2015.
- [20] P. A. Ascierto, H. J. Gogas, J. J. Grob, S. M. Algarra, P. Mohr, J. Hansson, *et al.*, “Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review,” *Crit. Rev. Oncol. Hematol.*, vol. 85, no. 2, pp. 149–161, 2013.
- [21] J. Lacour, F. Lacour, A. Spira, M. Michelson, J. Y. Petit, G. Delage, *et al.*, “Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial.,” *Br. Med. J. (Clin. Res. Ed.)*, vol. 288, no. 6417, pp. 589–592, 1984.
- [22] A. Laplanche, L. Alzieu, T. Delozier, J. Berlie, C. Veyret, P. Fargeot, *et al.*, “Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Federation Nationale des Centres de Lutte contre le Cancer (FNCLCC).,” *Breast Cancer Res. Treat.*, vol. 64, no. 2, pp. 189–191, 2000.
- [23] G. P. Dunn, A. T. Bruce, K. C. Sheehan, V. Shankaran, R. Uppaluri, J. D. Bui, *et al.*, “A critical function for type I interferons in cancer immunoediting,” *Nat Immunol*, vol. 6, no. 7, pp. 722–729, 2005.
- [24] L. Zitvogel, L. Galluzzi, O. Kepp, M. J. Smyth, and G. Kroemer, “Type I interferons in anticancer immunity,” *Nat Rev Immunol*, vol. 15, no. 7, pp. 405–414, Jul. 2015.

- [25] V. Brinkmann, T. Geiger, S. Alkan, and C. H. Heusser, "Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells," *J. Exp. Med.*, vol. 178, no. 5, p. 1655 LP-1663, 1993.
- [26] K. B. Nguyen, L. P. Cousens, L. A. Doughty, G. C. Pien, J. E. Durbin, and C. A. Biron, "Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox," *Nat. Immunol.*, vol. 1, no. 1, pp. 70–76, 2000.
- [27] S. J. Lee, B. C. Jang, S. W. Lee, Y. I. Yang, S. I. Suh, Y. M. Park, *et al.*, "Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)," *FEBS Lett*, vol. 580, no. 3, pp. 755–762, 2006.
- [28] L. V. Riella, A. M. Paterson, A. H. Sharpe, and A. Chandraker, "Role of the PD-1 Pathway in the Immune Response," *Am J Trans*, vol. 12, no. 10, pp. 2575–2587, 2012.
- [29] C. J. Aslakson and F. R. Miller, "Selective Events in the Metastatic Process Defined by Analysis of the Sequential Dissemination of Subpopulations of a Mouse Mammary Tumor," *Cancer Res*, vol. 52, no. 6, pp. 1399–1405, 1992.
- [30] B. L. Eckhardt, B. S. Parker, R. K. van Laar, C. M. Restall, A. L. Natoli, M. D. Tavarria, *et al.*, "Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix," *Mol Cancer Res*, vol. 3, no. 1, pp. 1–13, 2005.
- [31] M. Lelekakis, J. M. Moseley, T. J. Martin, D. Hards, E. Williams, P. Ho, *et al.*, "A novel orthotopic model of breast cancer metastasis to bone," *Clin Exp Metastasis*, vol. 17, no. 2, pp. 163–170, 1999.
- [32] A. E. Casey, W. R. Laster, and G. L. Ross, "Sustained Enhanced Growth of Carcinoma EO771 in C57 Black Mice," *Exp Biol Med*, vol. 77, no. 2, pp. 358–362, 1951.
- [33] D. Zanker, J. Waithman, J. W. Yewdell, and W. Chen, "Mixed Proteasomes Function To Increase Viral Peptide Diversity and Broaden Antiviral CD8+T Cell Responses," *J. Immunol.*, vol. 191, no. 1, p. 52 LP-59, 2013.
- [34] Broad Institute TCGA Genome Data Analysis Center, "Analysis-ready standardized TCGA data from Broad GDAC Firehose 2016\_01\_28 run." Broad Institute of MIT and Harvard, 2016.
- [35] N. Touati, K. Tryfonidis, F. Caramia, H. Bonnefoi, D. Cameron, L. Slaets, *et al.*, "Correlation between severe infection and breast cancer metastases in the EORTC 10994/BIG 1-00 trial: Investigating innate immunity as a tumor suppressor in breast cancer," *Ann. Oncol.*, vol. 27, no. suppl\_6, p. 256P–256P, 2016.
- [36] B. L. Eckhardt, P. A. Francis, B. S. Parker, and R. L. Anderson, "Strategies for the discovery and development of therapies for metastatic breast cancer," *Nat Rev Drug Discov*, vol. 11, no. 6, pp. 479–497, 2012.
- [37] H. Soliman, F. Khalil, and S. Antonia, "PD-L1 expression is increased in a subset of basal type breast cancer cells," *PLoS One*, vol. 9, no. 2, p. e88557, 2014.
- [38] B. Fu, F. Wang, R. Sun, B. Ling, Z. Tian, and H. Wei, "CD11b and CD27 reflect distinct

- population and functional specialization in human natural killer cells," *Immunology*, vol. 133, no. 3, pp. 350–359, 2011.
- [39] R. A. Seder and R. Ahmed, "Similarities and differences in CD4+ and CD8+ effector and memory T cell generation.," *Nat. Immunol.*, vol. 4, no. 9, pp. 835–842, 2003.
- [40] H. Cheon, E. C. Borden, and G. R. Stark, "Interferons and their stimulated genes in the tumor microenvironment," *Semin. Oncol.*, vol. 41, no. 2, pp. 156–173, 2014.
- [41] T. Bald, J. Landsberg, D. Lopez-Ramos, M. Renn, N. Glodde, P. Jansen, *et al.*, "Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation.," *Cancer Discov.*, vol. 4, no. 6, pp. 674–687, 2014.
- [42] J. M. Taube, A. Klein, J. R. Brahmer, H. Xu, X. Pan, J. H. Kim, *et al.*, "Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy," *Clin Cancer Res*, vol. 20, no. 19, pp. 5064–5074, 2014.
- [43] S. Adams, R. J. Gray, S. Demaria, L. Goldstein, E. A. Perez, L. N. Shulman, *et al.*, "Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199," *J Clin Oncol*, vol. 32, no. 27, pp. 2959–2966, 2014.
- [44] R. Salgado, C. Denkert, S. Demaria, N. Sirtaine, F. Klauschen, G. Pruneri, *et al.*, "The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014," *Ann. Oncol.*, vol. 26, no. 2, pp. 259–271, 2015.
- [45] D. A. Oble, R. Loewe, P. Yu, and M. C. Mihm, "Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human melanoma," *Cancer Immun. a J. Acad. Cancer Immunol.*, vol. 9, p. 3, 2009.
- [46] J. Liu, S. J. Blake, M. C. R. Yong, H. Harjunpää, S. F. Ngiew, K. Takeda, *et al.*, "Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease," *Cancer Discov.*, vol. 6, no. 12, pp. 1382–1399, 2016.
- [47] P. A. Beavis, N. Milenkovski, M. A. Henderson, L. B. John, B. Allard, S. Loi, *et al.*, "Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.," *Cancer Immunol. Res.*, vol. 3, no. 5, pp. 506–517, 2015.
- [48] G. T. Gibney, L. M. Weiner, and M. B. Atkins, "Predictive biomarkers for checkpoint inhibitor-based immunotherapy," *Lancet Oncol.*, vol. 17, no. 12, pp. e542–e551, 2017.
- [49] M. Banys, A. D. Hartkopf, N. Krawczyk, T. Kaiser, F. Meier-Stiegen, T. Fehm, *et al.*, "Dormancy in breast cancer," *Breast Cancer (London)*, vol. 4, pp. 183–191, 2012.
- [50] M. K. Callahan, M. A. Postow, and J. D. Wolchok, "CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic," *Front. Oncol.*, vol. 4, p. 385, 2014.
- [51] K. Rajani, C. Parrish, T. Kottke, J. Thompson, S. Zaidi, L. Ilett, *et al.*, "Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses," *Mol Ther*, vol. 24, no. 1. American Society

of Gene & Cell Therapy, pp. 166–174, 2016.

- [52] M. Mkrtychyan, N. Chong, R. Abu Eid, A. Wallecha, R. Singh, J. Rothman, *et al.*, “Anti-PD-1 antibody significantly increases therapeutic efficacy of *Listeria monocytogenes* (Lm)-LLO immunotherapy,” *J Immunother Cancer*, vol. 1, p. 15, 2013.
- [53] K. V Katlinski, J. Gui, Y. V Katlinskaya, A. Ortiz, R. Chakraborty, S. Bhattacharya, *et al.*, “Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment,” *Cancer Cell*, vol. 31, no. 2, pp. 194–207, Jul. 2017.
- [54] K. Iribarren, N. Bloy, A. Buqué, I. Cremer, A. Eggermont, W. H. Fridman, *et al.*, “Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy,” *Oncoimmunology*, vol. 5, no. 3, p. e1088631, Mar. 2016.

### Figure Legends

#### Figure 1: Enhanced IFN signaling correlates with increases in PD-L1 expression in TNBC

Cell surface PD-L1 expression determined by flow cytometry after staining with PE-conjugated anti-PD-L1 (M1H5) or isotype control (2A3). PD-L1 expression was measured in (A) untreated cells or (B) cells treated with IFN $\alpha$  (1000 IU/ml) or IFN $\gamma$  (10ng/ml) for 48 hours prior to flow cytometry. FACS data is represented as normalized mean fluorescence intensity (MFI).  $n = 3$ , error bars represent SEM; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; \*\*\*\*,  $P < 0.0001$  using Student's  $t$ -test. (C) Correlation table representing the correlation of PD-L1 RNA expression with an IFN core list (also shown as a scatter plot (D)) or full IFN signature in primary breast tumors ( $n = 1212$ ) from the TCGA RNAseq database. Pearson correlation coefficients ( $r$ ) are indicated. All  $P$  values are  $P < 0.0001$ .

#### Figure 2: IFN and type I IFN agonists increase PD-L1 expression in murine breast cancer cells *in vitro* and *in vivo*

Cell surface PD-L1 expression determined by flow cytometry after staining with PE-conjugated anti-PD-L1 (M1H5) or isotype (2A3). Cells were treated *in vitro* with (A) IFN $\alpha$  (1000 IU/ml) or IFN $\gamma$  (10ng/ml) for 48 hours or (B) transfected with poly(I:C) (10 $\mu$ g/ml) +/- MAR1 (10 $\mu$ g/ml) for 24 hours as indicated before PD-L1 expression was measured by flow cytometry ( $n = 3$ ). Error bars represent SEM. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; \*\*\*\*,  $P < 0.0001$  using Student's  $t$ -tests. (C) Immunohistochemical staining of PD-L1 expression in 4T1, 4T1.2 or E0771 primary tumors derived from mice that received IFN $\alpha$  (10<sup>5</sup> IU, I.P., thrice weekly), poly(I:C) (25 $\mu$ g, I.V., thrice weekly) or saline (as indicated) prior to primary tumor resection. Tissues were stained using goat anti-PD-L1 (1  $\mu$ g/ml) and PD-L1 expression visualized using DAB prior to nuclear counter-staining with hematoxylin. Representative pictures were taken of stained slides ( $n = 5$  mice per group). Scale bars indicate 50 $\mu$ m.

#### Figure 3: Antibody-mediated PD-1 blockade in combination with poly(I:C) reduces primary tumor weight

(A) Experimental protocol indicating timing of therapy in C57BL/6 mice inoculated IMFP

with  $1 \times 10^5$  EO771 cells and treated with poly(I:C) (25  $\mu$ g, IV) and anti-PD-1 (RPM1-14) (250  $\mu$ g, IP). (B) Tumor weight (mg) 15 days post tumor cell inoculation ( $n = 10$  per group). (C) Representative mCherry fluorescent imaging of *ex vivo* lungs collected from EO771 tumor bearing mice 30 days post-tumor cell inoculation (of 5 mice representative of larger cohort). (D) Total radiant efficiency of mCherry fluorescent lungs calculated using Living Image software (Lumina) ( $n = 5$  mice per group). Error bars represent SEM. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$  using Student's *t*-tests.

**Figure 4: Antibody-mediated blockade of the PD-1/PD-L1 axis in combination with poly(I:C) decreases primary tumor weight and increases systemic expansion of tumor-specific CD8<sup>+</sup> T cells**

(A) Treatment protocol for combination therapy of BALB/C mice inoculated IMFP with  $1 \times 10^5$  4T1.2 cells and treated with poly(I:C) (25  $\mu$ g, IV) and anti-PD-1 (RPM1-14) (250  $\mu$ g, IP). (B) Tumor weight (mg) 12 days post tumor cell inoculation ( $n = 15$  per group). Bioluminescent imaging of (C) whole mice and (D) *ex vivo* lungs collected from 4T1.2 tumor bearing mice 22 days post-inoculation ( $n = 5$  representative mice). (E) Relative tumor burden (RTB) in lungs of mice represents mCherry DNA expression compared to Vimentin ( $n = 15$  per group). (F) Single cell suspensions of lung were re-stimulated *in vitro* with 4T1.2 cells in the presence of BFA (10 $\mu$ g/ml). Following a five-minute incubation, CD8<sup>+</sup> T cells were assessed for IFN $\gamma$  production via flow cytometry after staining with APC-conjugated anti-CD8 $\alpha$  (53-6.7) and PE-conjugated anti-IFN $\gamma$  (XMG1.2) in an ICS assay. Absolute numbers per lung shown,  $n = 5$  per group. (G) Representative flow cytometry plots for IFN $\gamma$  and CD8 staining. Representative of two independent mouse experiments. Error bars represent SEM; \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; \*\*\*\*,  $P < 0.0001$  using Student's *t*-tests.

**Figure 5: Neoadjuvant poly(I:C) and combination therapy increases tumor infiltrating lymphocyte activation**

(A) Treatment protocol for combination therapy of BALB/C mice injected with  $1 \times 10^5$  4T1.2 cells IMFP and treated with poly(I:C) (25  $\mu$ g, IV) and anti-PD-1 (RPM1-14) (250  $\mu$ g, IP). (B) Tumor weight (mg) 12 days post tumor cell inoculation ( $n = 29$  per group; representative of 3 independent mouse experiments). (C) Absolute number of lymphocytes obtained from the primary tumor per gram. Proportion of (D) CD8<sup>+</sup>, CD4<sup>+</sup> and (E) NKp46<sup>+</sup> lymphocytes expressing CD69/NKG2D isolated from the primary tumor at the time of resection (D12). (F) Percentage of NKp46<sup>+</sup> lymphocytes expressing CD69/CD27/CD11b isolated from peripheral blood of 4T1.2 tumor bearing BALB/C mice at day 10.;  $n = 8$  per group, error bars represent SEM; \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$  \*\*\*\*,  $P < 0.0001$ ; using Student's *t*-test.

**Figure 6: Neoadjuvant poly(I:C) and combination therapy reduced metastatic burden**

Bioluminescent imaging after D-Luciferin injection (1.5mg, I.P) of (A) whole mice and (B) *ex vivo* lungs collected from 4T1.2 tumor-bearing mice 23 days after tumor inoculation (of 5 mice representative of larger cohort; mice skirted during imaging to block any possible bioluminescence from the lower half to focus purely on thoracic cavity metastases). (C) RTB in lungs represents mCherry tumor cell expression compared to Vimentin ( $n = 12$  per group).

(D) Single-cell suspensions of lung were re-stimulated *in vitro* with 4T1.2 cells in the presence of BFA (10 $\mu$ g/ml). Following a five-minute incubation, CD8<sup>+</sup> T cells were assessed for IFN $\gamma$  production via flow cytometry after staining with APC-conjugated anti-CD8 $\alpha$  (53-6.7) and PE-conjugated anti-IFN $\gamma$  (XMG1.2) in an ICS assay. Absolute numbers per lung shown,  $n = 5$  per group. (E) Representative flow cytometry plots for IFN $\gamma$  and CD8 staining. Representative of two independent mouse experiments. Error bars represent SEM; \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ ; \*\*\*\*,  $P < 0.0001$  using Student's  $t$ -tests.

**Figure 7: Neoadjuvant poly(I:C) combined with anti-PD-1 therapy prolonged survival**

(A, C) Treatment protocol for combination therapy of BALB/C mice injected with  $1 \times 10^5$  4T1.2 cells IMFP and treated with poly(I:C) (25  $\mu$ g, IV) and anti-PD-1 (RPM1-14) (250  $\mu$ g, IP). (B, D) Kaplan-Meier survival curve comparing metastasis-free survival in mice treated with vehicle, poly(I:C), anti-PD-1 (RMP1-14) or the combination [ $n = 15$  per group; Representative of two independent mouse experiments (B),  $n = 10$  per group (D)]. Mice excluded due to primary tumor regrowth are indicated. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*\*,  $P < 0.0001$  using Students  $t$ -test.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7

# Cancer Immunology Research

## Neoadjuvant Interferons: Critical for effective PD-1 based immunotherapy in TNBC

Natasha K. Brockwell, Katie L Owen, Damien Zanker, et al.

*Cancer Immunol Res* Published OnlineFirst August 28, 2017.

<b>Updated version</b>	Access the most recent version of this article at: doi: <a href="https://doi.org/10.1158/2326-6066.CIR-17-0150">10.1158/2326-6066.CIR-17-0150</a>
<b>Supplementary Material</b>	Access the most recent supplemental material at: <a href="http://cancerimmunolres.aacrjournals.org/content/suppl/2017/09/01/2326-6066.CIR-17-0150.DC1">http://cancerimmunolres.aacrjournals.org/content/suppl/2017/09/01/2326-6066.CIR-17-0150.DC1</a>
<b>Author Manuscript</b>	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

<b>E-mail alerts</b>	<a href="#">Sign up to receive free email-alerts</a> related to this article or journal.
<b>Reprints and Subscriptions</b>	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a> .
<b>Permissions</b>	To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a> .